Dr. David Yen Tang Chen, MD

Dr. Chen practices at Fox Chase Cancer Center in Philadelphia, Pennsylvania, part of Thomas Jefferson University.

Dr. Chen's NPI, 1841226081, was assigned on June 22, 2006. Dr. Chen graduated from Weill Cornell Medicine in 1997. Dr. Chen holds Pennsylvania license MD424133.

Dr. Chen's primary practice is Fox Chase Cancer Center, at 333 Cottman Avenue, Philadelphia, PA 19111.

Dr. Chen's primary practice is Fox Chase Cancer Center in Philadelphia, Pennsylvania, part of Thomas Jefferson University. Dr. Chen is also affiliated with Temple University Hospital. The medical group on file is Temple Faculty Physicians. Dmand AI also links Dr. Chen to 3 more hospitals, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chen practices, 6 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Chen's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Chen is board certified in urology by the American Board of Urology. Dmand AI has Dr. Chen's licenses on file in 3 states: Pennsylvania, New Jersey and New York.

Dmand AI lists bladder removal, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, prostate cancer and prostate surgery among the conditions Dr. Chen treats.

CMS data shows 903 Medicare services from Dr. Chen across 13 procedure codes in 2024, for 525 Medicare patients. Medicare paid $81,611 for them.

CMS counts 525 Medicare patients who saw Dr. Chen in 2024. The largest group is 65 to 74, with 303 patients. 75% of them have cancer, and 75% have high blood pressure. 4% are also on Medicaid. Their average risk score is 1.12, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Chen's median patient age at 71, with 12% women.

In 2024, Dr. Chen wrote 238 Medicare Part D claims for 64 patients. 94% of them were for generic drugs. CMS names the drug for 155 of them, across 4 drugs with 11 or more claims each, at $2,465 in total drug cost. In 2023, CMS named 164 claims across 5 drugs.

Dr. Chen accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chen as offering telehealth. CMS counts 16 procedures of prostate resection by Dr. Chen, more than 74% of the clinicians it reports for that procedure.

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 126 papers to Dr. Chen, published from 2007 to 2024. 2021 was the busiest year, with 8. The most frequent topics are Kidney Neoplasms, Prostatic Neoplasms and Carcinoma, Renal Cell. Dr. Chen has published most often in J Urol. Dr. Chen's most frequent co-authors are Richard Evan Greenberg, MD, Eric Mark Horwitz, MD and Rosalia Viterbo, MD.

Dmand AI links Dr. Chen to 12 clinical trials, 6 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Carcinoma, Transitional Cell, Carcinoma, Renal Cell and Prostatic Neoplasms. Fox Chase Cancer Center sponsors the most, 5.

CMS Open Payments shows 131 general payments to Dr. Chen from 35 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 72% of the total. Medtronic, Inc. paid the most, $775.

Dmand AI lists 2 awards for Dr. Chen, most recently ACS Fellow in 2013. Dr. Chen serves on SUO Fellowship Committee.

Dr. Chen graduated from Weill Cornell Medicine in 1997. Dr. Chen is a member of ACS and AUA.

Dr. Chen is in network with 19 carriers, including Aetna, Elevance and Highmark. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.